Automated Cell Market Share and Size 2023 Growth By Key Players, Trend
Posted by Roger on December 6th, 2023
The automated cell counters market is estimated to be valued at US$ 3.75 Bn in 2023 and is expected to exhibit a CAGR of 7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Automated cell counters help analyze cell viability, concentration and size automatically. These systems are reliable, accurate and efficient for enumeration of various cell types such as blood, bacteria and yeast cells. These counters are useful in research activities, hematology, microbiology and cell biology applications.
Market key trends:
Rapid adoption of automated cell counters for research activities is estimated to be a major trend fueling market growth over the forecast period. Cell counting is an important step in various fields of research such as cancer, stem cell and clinical research. Automated cell counters streamline cell counting process and provide reliable results, thereby witnessing increasing adoption over manual cell counting methods. For example, in cancer research, cell counters help effectively count cancer cell numbers to study the efficacy of new drug candidates. Growing research expenditure globally is also expected to boost the demand for automated cell counters for research purposes during the forecast period.
Porter's Analysis
Threat of new entrants: New entrants face high initial costs for R&D, manufacturing facilities, and distribution network. Bargaining power of buyers: Large diagnostic labs and hospitals have significant bargaining power over suppliers due to their high purchase volumes. Bargaining power of suppliers: A few major players dominate the market, giving them strong bargaining power over buyers. Threat of new substitutes: Alternatives like manual cell counting have limited accuracy and are time-consuming. Competitive rivalry: Intense competition exists among key players to introduce innovative products and services.
SWOT Analysis
Strengths: Automated cell counters provide accurate, fast, and reproducible results. Growing adoption in biotechnology and pharmaceutical industries.
Weaknesses: High initial costs of instruments limit affordability for small labs. Require regular maintenance and calibration.
Opportunities: Rising global healthcare expenditure on preventive healthcare and diagnostics. Growing demand in emerging markets like Asia Pacific and Latin America.
Threats: Stringent regulatory environment for approval of new instruments. Threat from refurbished instruments diluting revenues of major players.
Key Takeaways
The global automated cell counters market is expected to witness high growth, exhibiting CAGR of 7.0% over the forecast period, due to increasing demand for disease diagnosis and drug discovery.
The North American region dominated the market in 2023 with a share of over 35%, due to presence of large biotechnology and pharmaceutical companies and advanced healthcare infrastructure in the region. The Asia Pacific region is anticipated to grow at the fastest pace during the projected timeframe owing to rising healthcare spending, increasing number of contract research organizations, and growing geriatric population.
Key players operating in the automated cell counters are Thermo Fisher Scientific, Danaher Corporation, Agilent Technologies, PerkinElmer Inc., Bio-Rad Laboratories, BD, Merck KGaA, Logos Biosystems, Corning Incorporated, and Tecan. Thermo Fisher Scientific holds the leading market share backed by its robust product portfolio and global presence. BD and Danaher Corporation hold the second and third position respectively in the global market.
